Pharvaris Aktie

Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » Altro su de.investing.com

Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » Altro su de.investing.com